Exposure-Safety Analyses Identify Predictors of Change in Bone Mineral Density and Support Elagolix Labeling for Endometriosis-Associated Pain.
Level 3 - non-randomized controlled study
Exposure-response pharmacometric modeling using pooled data from four phase III clinical trials
PubMed 32945631 · doi:10.1002/psp4.12560
What was done
Researchers developed a population exposure-response model to evaluate the relationship between elagolix exposure and changes in bone mineral density (BMD) using pooled data from four phase III clinical trials in premenopausal women with endometriosis-associated pain. The pharmacokinetic exposure-dependent changes in BMD were modeled using an indirect-response maximum effect (Emax) structure mediated by bone resorption stimulation. Covariates affecting baseline BMD and bone formation rates were identified, and simulations were performed to predict BMD loss after 24 months of 150 mg once-daily dosing.
What was found
African American race, higher body mass index (BMI), and lower baseline type-I collagen C-telopeptide concentrations were significantly associated with higher baseline BMD. Higher BMI was also significantly associated with increased bone formation rates. Model simulations projected that elagolix 150 mg once daily for 24 months causes a -1.45% (-2.04% to -0.814%) change from baseline in BMD.
Why it matters
This exposure-response analysis characterizes the bone resorption kinetics associated with elagolix-induced hypoestrogenism, providing quantitative support for regulatory labeling and duration limits for endometriosis treatment.
Limits
The abstract does not report the total participant count (n), the specific clinical trial identifiers, or observed clinical fracture outcomes. Predictions rely on model-based simulations rather than directly observed empirical 24-month BMD measurements, and post-treatment BMD recovery kinetics are not reported.